Akaza Eriko, Yuzawa Mitsuko, Matsumoto Yoko, Kashiwakura Shiho, Fujita Kyoko, Mori Ryusaburo
Department of Ophthalmology, Surugadai Hospital of Nihon University, Kanda, Tokyo, Japan.
Jpn J Ophthalmol. 2007 Jul-Aug;51(4):270-7. doi: 10.1007/s10384-007-0452-3. Epub 2007 Aug 3.
To determine the efficacy of photodynamic therapy (PDT) with verteporfin for polypoidal choroidal vasculopathy (PCV).
PDT was performed in 35 patients (35 eyes) with PCV. We evaluated the number of treatments and compared visual acuity (VA), ophthalmological findings, and changes in polypoidal lesions and branching vascular networks by measuring lesion diameters using Heidelberg retina angiography before PDT, and then every 3 months for 1 year after PDT.
The mean annual number of treatment sessions was 2.2. VA was improved or maintained in 80% of the patients. Retinal pigment epithelium detachment, retinal detachment, hemorrhage, and/or exudates disappeared in 69%, and leakage resolved in 74% of the patients. Polypoidal lesions disappeared completely on indocyanine green angiography in 83% of the patients. All branching vascular networks persisted. Polypoidal lesions had recurred at the termini of the remaining branching vascular networks at 9 months after the first PDT in two eyes and at 12 months in one eye.
PDT with verteporfin for PCV appears to improve or maintain VA for the first posttreatment year. Approximately 70% of PCV cases showed improved ophthalmoscopic findings. However, as polypoidal lesions recur after PDT in some cases, further study is needed to confirm the long-term efficacy of PDT for PCV.
确定维替泊芬光动力疗法（PDT）治疗息肉样脉络膜血管病变（PCV）的疗效。
对35例（35只眼）PCV患者进行PDT治疗。我们评估了治疗次数，并通过使用海德堡视网膜血管造影术在PDT前测量病变直径，然后在PDT后1年每3个月测量一次，比较了视力（VA）、眼科检查结果以及息肉样病变和分支血管网络的变化。
平均每年治疗次数为2.2次。80%的患者视力得到改善或维持。69%的患者视网膜色素上皮脱离、视网膜脱离、出血和/或渗出物消失，74%的患者渗漏消退。83%的患者吲哚菁绿血管造影显示息肉样病变完全消失。所有分支血管网络均持续存在。在两只眼中，首次PDT后9个月，在一只眼中12个月时，息肉样病变在剩余分支血管网络的末端复发。
维替泊芬PDT治疗PCV在治疗后的第一年似乎能改善或维持视力。约70%的PCV病例眼科检查结果有所改善。然而，由于某些情况下PDT后息肉样病变会复发，需要进一步研究以证实PDT治疗PCV的长期疗效。
